MediPal Holdings (7459) Q1 2025 earnings summary

Executive summary

• Net sales increased by 2.5% year-over-year to ¥909,317 million for the quarter ended June 30, 2024, with growth across all business segments.

• Operating profit rose 7.1% year-over-year to ¥13,283 million, driven by business expansion and improved gross margin.

• Profit attributable to owners of parent declined 19.5% year-over-year to ¥9,008 million due to lower extraordinary income compared to the prior year.

• Comprehensive income decreased 33.0% year-over-year to ¥15,102 million.

Financial highlights

• Gross profit increased 5.5% year-over-year to ¥62,598 million, with gross margin improving to 6.88%.

• SG&A expenses rose 5.1% year-over-year to ¥49,314 million, mainly due to business expansion.

• Ordinary profit grew 1.4% year-over-year to ¥16,916 million.

• Total assets reached ¥1,814,497 million, up ¥15,370 million from March 31, 2024.

• Net assets increased to ¥741,635 million, with a net worth ratio of 33.3%.

Outlook and guidance

• Full-year net sales forecast at ¥3,660,000 million, up 2.8% year-over-year.

• Operating profit projected at ¥50,000 million (+5.6%), ordinary profit at ¥66,000 million (+2.2%), and profit attributable to owners of parent at ¥33,500 million (−19.2%).

• Earnings per share forecast at ¥160.87, reflecting the impact of a share buyback.

• Annual dividend forecast maintained at ¥60 per share.